Most Read Articles
Jairia Dela Cruz, 05 Oct 2020
Drinking more than two cups of coffee per day may just be the intervention that prevents hundreds of thousands of liver disease‐related deaths globally, a study reports.
Pearl Toh, 21 Sep 2020
Early and sustained treatments with simplified regimen are the key to achieving good asthma control, said experts during a presentation at the ERS 2020 Congress.
Roshini Claire Anthony, 12 Oct 2020

Insulin icodec, an in-development basal insulin analogue administered once weekly, was as effective as once-daily insulin glargine in patients with type 2 diabetes (T2D) insufficiently controlled with metformin with or without a DPP-4* inhibitor, according to a phase II trial presented at EASD 2020.

Stephen Padilla, Yesterday
Use of systemic corticosteroids does not reduce in-hospital mortality for patients with severe or critical coronavirus disease (COVID-19), which is in stark contrast to that observed in the RECOVERY clinical trial, according to a study in Wuhan, China.

Crisaborole ointment reduces AD lesions

Elaine Soliven
15 Jan 2019
Dr Robert Bissonnette Photo credit: ISDS 2018

The non-steroidal phosphodiesterase-4 inhibitor crisaborole may reduce lesions in patients with mild-to-moderate atopic dermatitis (AD), according to an intrapatient randomized study presented at the Inflammatory Skin Disease Summit (ISDS) 2018.

This phase IIa, single-centre, placebo-controlled trial enrolled 40 patients (aged ≥18 years) with mild-to-moderate AD (two target lesions of ≥3 cm2). Target lesions of each patient were randomized in a 1:1 ratio to have either crisaborole ointment 2% or placebo applied twice daily for a 15-day double-blind period, followed by another application of crisaborole twice daily for an additional 28-day open-label period. The study’s primary endpoint was the change from baseline in target lesion total sign score (TSS) at 15 days of follow-up. Investigator’s Static Global Assessment (ISGA) and pruritus numeric rating scale (NRS) were also measured to assess lesion severity. [ISDS 2018, abstract 117]

At 15 days, lesions treated with crisaborole had a significantly greater reduction in TSS from baseline compared with those treated with placebo (change from baseline, -4.5 vs -2.1; p<0.0001).

More crisaborole-treated lesions also achieved a significantly greater reduction in ISGA from baseline than placebo-treated lesions (change from baseline, -1.9 vs -0.8; p<0.0001).

Of note, at 1 day after the first application of crisaborole ointment, researchers found that there was significant improvement in pruritus NRS for the lesions treated with crisaborole than those treated with placebo (-1.9 vs 1.0; p=0.0188), which “continued to improve or was maintained through day 15,” said lead author Dr Robert Bissonnette from Innovaderm Research Incorporated in Montreal, Quebec, Canada.

Application site pain/pruritus adverse event (AE) occurred more frequently for the placebo-treated lesions at 12.5 percent (n=5) compared with the crisaborole-treated ones at 7.5 percent (n=3). However, no patients discontinued treatment due to this AE.

“[The] crisaborole [treatment] was well tolerated, significantly reduced lesion AD signs, and improved lesion pruritus within 1 day after [the] initial application in adults with mild-to-moderate AD,” Bissonnette concluded.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Doctor - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Jairia Dela Cruz, 05 Oct 2020
Drinking more than two cups of coffee per day may just be the intervention that prevents hundreds of thousands of liver disease‐related deaths globally, a study reports.
Pearl Toh, 21 Sep 2020
Early and sustained treatments with simplified regimen are the key to achieving good asthma control, said experts during a presentation at the ERS 2020 Congress.
Roshini Claire Anthony, 12 Oct 2020

Insulin icodec, an in-development basal insulin analogue administered once weekly, was as effective as once-daily insulin glargine in patients with type 2 diabetes (T2D) insufficiently controlled with metformin with or without a DPP-4* inhibitor, according to a phase II trial presented at EASD 2020.

Stephen Padilla, Yesterday
Use of systemic corticosteroids does not reduce in-hospital mortality for patients with severe or critical coronavirus disease (COVID-19), which is in stark contrast to that observed in the RECOVERY clinical trial, according to a study in Wuhan, China.